Literature DB >> 18342780

A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Gerhard C Hildebrandt1, Krystyna M Olkiewicz, Leigh Corrion, Shawn G Clouthier, Elizabeth M Pierce, Chen Liu, Kenneth R Cooke.   

Abstract

Idiopathic pneumonia syndrome (IPS) is a frequently fatal complication following allogeneic stem cell transplantation (allo-SCT). Experimental models have revealed that TNF-alpha contributes to pulmonary vascular endothelial cell (EC) apoptosis, and modulates the infiltration of donor leukocytes into the lung parenchyma. The inflammatory effects of TNF-alpha are mediated by signaling through the type I (TNFRI) or type II (TNFRII) TNF receptors. We investigated the relative contribution of TNFRI and TNFRII to leukocyte infiltration into the lung following allo-SCT by using established murine models. Wild-type (wt) B6 mice or B6 animals deficient in either TNFRI or TNFRII were lethally irradiated and received SCT from allogeneic (LP/J) or syngeneic (B6) donors. At week 5 following SCT, the severity of IPS was significantly reduced in TNFRII-/- recipients compared to wt controls, but no effect was observed in TNFRI-/- animals. Bronchoalveolar lavage fluid (BALF) levels of RANTES and pulmonary ICAM-1 expression in TNFRII-/- recipients were also reduced, and correlated with a reduction of CD8(+) cells in the lung. Pulmonary inflammation was also decreased in TNFRII-/- mice using an isolated MHC class I disparate model (bm1 --> B6), and in bm1 wt mice transplanted with B6 TNF-alpha-/- donor cells. Collectively, these data demonstrate a role for TNF-alpha signaling through TNFRII in leukocyte infiltration into the lung following allo-SCT, and suggest that disruption of the TNF-alpha:TNFRII pathway may be an effective tool to prevent or treat IPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342780      PMCID: PMC2390587          DOI: 10.1016/j.bbmt.2008.01.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  71 in total

1.  Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.

Authors:  A N Liu; A Z Mohammed; W R Rice; D T Fiedeldey; J S Liebermann; J A Whitsett; T J Braciale; R I Enelow
Journal:  Am J Respir Cell Mol Biol       Date:  1999-05       Impact factor: 6.914

Review 2.  The tumor necrosis factor ligand and receptor families.

Authors:  F Bazzoni; B Beutler
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

3.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.

Authors:  M Grell; G Zimmermann; E Gottfried; C M Chen; U Grünwald; D C Huang; Y H Wu Lee; H Dürkop; H Engelmann; P Scheurich; H Wajant; A Strasser
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

4.  Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice.

Authors:  L A Ortiz; J Lasky; G Lungarella; E Cavarra; P Martorana; W A Banks; J J Peschon; H L Schmidts; A R Brody; M Friedman
Journal:  Am J Respir Cell Mol Biol       Date:  1999-04       Impact factor: 6.914

5.  Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells.

Authors:  G Monastra; A Cabrelle; A Zambon; A Rosato; B Macino; D Collavo; P Zanovello
Journal:  Cell Immunol       Date:  1996-07-10       Impact factor: 4.868

6.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.

Authors:  M Grell; E Douni; H Wajant; M Löhden; M Clauss; B Maxeiner; S Georgopoulos; W Lesslauer; G Kollias; K Pfizenmaier; P Scheurich
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

7.  Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75.

Authors:  K C Sheehan; J K Pinckard; C D Arthur; L P Dehner; D V Goeddel; R D Schreiber
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

8.  Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome.

Authors:  G E Grau; N Mili; J N Lou; D R Morel; B Ricou; R Lucas; P M Suter
Journal:  Lab Invest       Date:  1996-04       Impact factor: 5.662

9.  The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients.

Authors:  S A Yousem
Journal:  Hum Pathol       Date:  1995-06       Impact factor: 3.466

10.  Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro.

Authors:  J Rothe; F Mackay; H Bluethmann; R Zinkernagel; W Lesslauer
Journal:  Circ Shock       Date:  1994-10
View more
  9 in total

1.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

2.  Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

Authors:  J W Chien; M Sakai; T A Gooley; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-06-29       Impact factor: 5.483

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 4.  Translational research efforts in biomarkers and biology of early transplant-related complications.

Authors:  Sophie Paczesny; Maribel Diaz-Ricart; Enric Carreras; Enrique Carerras; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation.

Authors:  Daniela M Schlatzer; Jean-Eudes Dazard; Rob M Ewing; Serguei Ilchenko; Sara E Tomcheko; Saada Eid; Vincent Ho; Greg Yanik; Mark R Chance; Kenneth R Cooke
Journal:  Mol Cell Proteomics       Date:  2012-02-15       Impact factor: 5.911

6.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

7.  Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression.

Authors:  Unni M Chandrasekharan; Lisa Dechert; Uchechukwu I Davidson; Matthew Waitkus; Lori Mavrakis; Katherine Lyons; Jordan R Beach; Xiaoxia Li; Thomas T Egelhoff; Paul L Fox; Paul E DiCorleto
Journal:  Sci Signal       Date:  2013-07-16       Impact factor: 8.192

8.  Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.

Authors:  Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan
Journal:  Ann Am Thorac Soc       Date:  2021-03

9.  Allogeneic splenocyte transfer and lipopolysaccharide inhalations induce differential T cell expansion and lung injury: a novel model of pulmonary graft-versus-host disease.

Authors:  Tereza Martinu; Christine V Kinnier; Jesse Sun; Francine L Kelly; Margaret E Nelson; Stavros Garantziotis; W Michael Foster; Scott M Palmer
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.